Abstract
Background Although longitudinal changes in plasma phosphorylated tau 181 (p-tau181) and neurofilament light (NfL) correlate with Alzheimer’s disease (AD) progression, it is unknown whether these changes can be used to monitor drug effects in preventive clinical trials. Here, we tested the utility of changes in plasma p-tau181 and NfL as surrogate biomarkers for clinical trials focusing on cognitively unimpaired (CU) individuals.
Methods We evaluated 257 CU older individuals with amyloid-beta (Aβ) positron emission tomography (PET) at baseline, as well as the baseline, up to 24-month plasma p-tau181 and NfL measures. Linear regressions and Cox-proportional hazards tested the associations of change in markers with age and clinical progression, respectively. We estimated the sample size needed to test a 25% drug effect with 80% of power at a 0.05 level on reducing changes in plasma markers.
Results Longitudinal changes in plasma NfL were associated with age, while changes in plasma p-tau181 with progression to amnestic MCI. Clinical trial using p-tau181 and NfL would require 78% and 63% smaller sample sizes, respectively, for a 24-month than a 12-month follow-up. The use of Aβ positivity for enrichment had a larger impact on reducing the sample size required for trials using p-tau181 (43% reduction) than NfL (17%) as surrogate. Notably, population enrichment with intermediate levels of Aβ, rather than merely Aβ positivity, reduced the sample size by 88% for p-tau181 and 64% for NfL over 12 months, and by 73% for p-tau181 and 59% for NfL over 24 months.
Conclusion Our results highlighted that changes in plasma NfL could be used as a surrogate for age-related degeneration, while longitudinal changes in plasma p-tau181 were associated with parallel clinical progression. A follow-up duration of 24 months was associated with more stable changes in plasma measures and, consequently, a greater effect size than a follow-up period of 12 months. The enrollment of CU subjects with intermediate levels of Aβ constitutes the alternative with the largest effect size for clinical trials quantifying plasma p-tau181 and NfL over 12 and 24 months.
1. Introduction
The preclinical stage of Alzheimer’s Disease (AD) has recently become the focus of clinical trials, based on the assumption that better therapeutic outcomes can be achieved before the onset of major neurodegeneration, Aβ and tau pathologies, and cognitive decline1, 2. The presence of abnormal biomarkers of Aβ plaques and tau tangles, and a lack of objective cognitive symptoms are key features of preclinical AD3. Even though these individuals present an elevate risk for cognitive decline, the vast majority will remain clinically stable during typical clinical trial periods of 12- to 24-month follow-up4. This challenges the use of changes in cognitive measures as a single primary outcome of therapeutical trials in cognitively unimpaired (CU) individuals5. In this context, the use of surrogate biomarkers of disease progression can be a useful addition.
Positron emission tomography (PET) and cerebrospinal fluid (CSF) biomarkers can reliably capture brain Aβ and tau pathologies, while magnetic resonance imaging (MRI) can detect neurodegenerative changes that result in atrophy. All three measures have already been proposed to monitor AD progression in clinical trials6-9. Recently, simpler, and more cost-effective blood-based biomarkers have been developed to estimate the presence of AD-related pathologies in the human brain10, 11. Plasma neurofilament light (NfL) has exhibited high sensitivity to detect neurodegeneration in AD12-14, and is associated with aging in CU individuals13, 15. Plasma phosphorylated tau (p-tau) presents both high sensitivity and specificity for detecting AD pathophysiology16-18 and for predicting AD-related clinical progression16, 19-21. Together, these results indicate that these novel blood biomarkers have the potential to be used to monitor participants’ disease progression in preventive clinical trials in CU individuals.
Although recent studies have shown that plasma biomarkers can be useful for AD clinical trials22, these investigations exclusively evaluated the role of plasma biomarkers in the selection of individuals that are more likely to progress over time (population enrichment). The possible utility of longitudinal changes in plasma biomarkers as a surrogate outcome measurement in CU individuals remains unexplored in the literature. Here, we tested the hypothesis that longitudinal changes in plasma NfL and p-tau181 levels can be used to monitor therapeutic response in clinical trials focusing on CU older individuals.
2. Materials and methods
Data used in the preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (http://adni.loni.usc.edu; last accessed March 2022). Under the leadership of principal investigator Michael W. Weiner, MD, the ADNI was launched in 2003 as a public-private initiative. ADNI study was conducted according to Good Clinical Practice guidelines, US 21CFR Part 50 – Protection of Human Subjects, and Part 56 – Institutional Review Boards, and pursuant to state and federal HIPAA regulations and was approved by the Institutional Review Board of each participating site. It is a longitudinal multicenter study that has been recruiting participants from more than 50 sites across the United States and Canada. Detailed information concerning inclusion and exclusion criteria has been described previously23. Written informed consent for the study was obtained from all participants and/or authorized representatives. We included 257 CU older who had available data on plasma p-tau181 and NfL in at least two visits along with [18F]florbetapir amyloid (Aβ)-PET at the time of first plasma measurement. CU individuals had Mini-Mental State Examination (MMSE) score of 24 or higher and a clinical dementia rating (CDR) of 0. They did not have any significant neurological disease.
2.1 Imaging analysis
Aβ positivity was estimated using [18F]florbetapir PET. The standardized uptake value ratio (SUVR) images were acquired using the whole cerebellum grey matter as the reference region. A cortical composite of [18F]florbetapir was calculated by averaging SUVRs in the cortical gray matter of frontal, anterior and posterior cingulate, lateral parietal, and temporal regions. Aβ positivity was determined whether the composite value was greater than 1.11, based on previous validation studies24, 25. We used SUVR value and equations previously established by the ADNI PET core26 to transform the Aβ-PET SUVR to the Centiloid scale27. Based on ongoing clinical trials, the individuals with Centiloid values between 20-40 were classified as having intermediate Aβ levels28.
2.2 Plasma quantification
Plasma samples were collected and stored following ADNI protocols (http://adni.loni.usc.edu/methods/). The plasma p-tau18110 and NfL29 assays were measured on single molecule array (Simoa)_HD-X instruments (Quanterix, Billerica, MA, USA) at the Clinical Neurochemistry Laboratory, University of Gothenburg, Mölndal, Sweden. Baseline p-tau181 and NfL levels were considered outliers and excluded if their value was higher than three standard deviations of the population as proposed in the previous studies19. Based on this criterion, 10 individuals were excluded from the analyses.
2.3 Statistical methods
The statistical analyses were performed using R statistical software version 4.0.5 (http://www.r-project.org/). Associations between biomarkers were tested using Pearson correlation. The slope of change of plasma p-tau181 and plasma NfL levels were calculated using linear mixed-effects (LME) models with subject-specific random slopes and intercepts, as follows:
β0 represents the intercept;
Timeij represents the effect of time, fitted as a continuous measure in years from baseline;
υ0i is the subject-specific variation from the average intercept effect.
Time-to-event analysis was carried out to evaluate the risk of clinical progression to mild cognitive impairment (MCI). Adjusted hazard ratios (HRs) were calculated using Cox-proportional hazards models that were fitted with the following predictors: group, age, and years of education. The percentage of change in biomarkers was calculated between follow-up and baseline as follows:
. The effect size was calculated as the mean of change in biomarker in the group divided by the standard deviation7. We estimated the sample size required for a clinical trial testing a hypothesized 25% drug effect on longitudinal reduction in biomarker6, 7, 30 with 80% of power at a 5% level using a well-validated formula7, 31 (Figure 1). We used 12-month changes in tau-PET (18F-flortaucipir SUVR in the temporal lobe) and structural MRI (whole cortex atrophy assessed with tensor-based morphology)7 in Aβ positive individuals previously reported in the literature to estimate the sample size for clinical trials using neuroimaging biomarkers as surrogate outcomes.
(A) Previous studies assessed (cross-sectionally) the utility of plasma markers for selecting individuals most likely to progress over time (population enrichment). (B) In the present study, we evaluated the utility of plasma biomarkers to monitor drug effects (longitudinally).
3. Results
A total of 257 CU participants [45.5% males; mean age at baseline = 72.8 (6.16) years] were included in this study of whom 32.3% were Aβ positive. Demographics and key characteristics of the population are summarized in Table 1 and Supplemental Figure 1.
3.1 Changes in plasma biomarkers as a function of their baseline levels
We observed a negative correlation between baseline plasma p-tau181 levels and its slope of change over 24 months follow-up (r = −0.17, P = 0.0012). By contrast, we found a positive association between baseline plasma NfL concentrations and plasma NfL slope of change (r = 0.59, P < 0.001) (Supplemental Figure 2).
3.2 Association of change in plasma biomarkers with age and clinical progression
Longitudinal changes in plasma p-tau181 were not significantly correlated with age (r = 0.09, P = 0.087, Supplemental Figure 3), while longitudinal plasma NfL significantly correlated with participants’ age (r = 0.48, P < 0.001, Supplemental Figure 3). On the other hand, changes in plasma p-tau181 were significantly associated with an increased risk of clinical progression to MCI over 24 months (P = 0.037, Figure 2), whereas changes in plasma NfL were not (P = 0.263, Figure 2).
The squares represent the hazard ratio values for a clinical progression from CU to MCI over 24 months. The model was adjusted for age and years of education.
3.3 Longitudinal change and effect size of plasma biomarkers
The percentage of change in plasma p-tau181 and NfL (and their effect sizes) were calculated at 12- and 24-month follow-up visits in relation to their baseline values (Figure 3A-B; Supplemental Figure 4). Changes in plasma p-tau181 and NfL were not significantly different from zero over 12 months in the whole population, Aβ positive, or individuals with intermediate Aβ levels. In contrast, we found a significant increase in the percentage of change of plasma p-tau181 at 24 months [CU whole population, mean: 13.84 % (95% CI, 6.4 to 21.24); Aβ negative, mean: 11.52% (95% CI, 2.8 to 20.4); Aβ positive, mean: 12.6% (95% CI, 2.2 to 23.1); intermediate Aβ ranges, mean 17.11% (95% CI, 2.9 to 31.25)]. P-tau181 effect size was numerically higher in 24 months (CU whole population: 0.23; Aβ negative: 0.21; Aβ positive: 0.34; intermediate Aβ levels: 0.44) than at 12 months (CU whole population: 0.08; Aβ negative: 0.09; Aβ positive: 0.14; intermediate Aβ levels: 0.28) for all groups. Similarly, we observed a significant increase in plasma NfL at 24 months [CU whole population, mean: 12.03 % (95% CI, 7.9 to 16.15); CU Aβ negative, mean: 11.5 % (95% CI, 6.3 to 16.3); Aβ positive, mean: 14.1% (95% CI, 6.2 to 22.1); intermediate Aβ levels, mean 19.45% (95% CI, 8.4 to 30.5)]. NfL effect size was higher at 24 months (CU whole population: 0.38; CU Aβ negative: 0.39; CU Aβ positive: 0.41; intermediate Aβ levels: 0.58) than 12 months (CU whole population: 0.24; Aβ negative: 0.28; Aβ positive: 0.25; intermediate Aβ levels: 0.39).
The bar plots show the percentage of changes with their respective 95% confidence intervals for plasma (A) p-tau181 and (B) NfL concentrations in CU older individuals over 12 months and over 24 months in relation to the biomarker value at the baseline visit. The 12- and 24-month follow-ups showed a similar annualized rate of progression. The effect size at 24 months was larger due to both a greater mean of progression and a relatively more stable change among participants (smaller standard deviation (SD)). The effect size was calculated as the ratio between the mean and SD of the percentage of change overtime points. The higher the effect size, the smaller the measure’s variability, which indicates a more precise populational estimate. (*) indicates that the 95% confidence interval did not cross the zero line, and therefore, the longitudinal progression was significantly different from zero.
3.4 Sample size required for clinical trials in CU individuals
We estimated the sample size required for a clinical trial performed over 12- and 24-months using plasma p-tau181 or NfL as surrogate markers. Therapeutic clinical trials performed over 24 months would require 78% and 63% smaller sample sizes than 12-month clinical trials using plasma p-tau181 and NfL, respectively (Table 2).
A 24-month clinical trial using plasma p-tau181 as a surrogate marker, including the entire CU population, would require 4,442 individuals per study arm. In comparison, a clinical trial including only CU Aβ positive would require 2,520 individuals per study arm (reduction of 43%), and a trial with intermediate Aβ levels would require 1,216 individuals per study arm (reduction of 73%) (Figure 4A). A 24-month clinical trial using plasma NfL as a surrogate marker, including the entire CU population, would require 1,724 individuals per study arm. In comparison, a clinical trial including only CU Aβ positive would require 1,432 individuals per study arm (reduction of 32%), and a trial with intermediate Aβ levels would require 698 individuals per study arm (reduction of 59%) (Figure 4A).
(A) Sample sizes required for hypothetical clinical trials powered to use plasma biomarkers to monitor drug effects in CU older whole population, Aβ positive or intermediate Aβ deposition (Centiloid 20-40). (B) Estimated cost with surrogate neuroimaging (Jack et al.7) and plasma (this study) biomarkers only for clinical trials powered to use changes in these biomarkers to monitor drug effects. (C) The estimated cost of biomarkers plus the costs with some of the other necessary tests that are influenced by total sample sizes, such as costs with the definition of Aβ positivity (using PET) for population enrichment and the standard clinical evaluations for each participant. The figure shows that using changes in plasma p-tau181 as a surrogate would reduce costs - in relation to a trial using tau-PET - if we only consider the cost with the surrogate biomarker, but not when other necessary costs that increase with sample size are considered. The costs of clinical trials using changes in tau-PET (18F-flortaucipir uptake in the temporal lobe) or structural MRI (tensor-based morphology cortical volume) as surrogate were estimated based on the mean and SD of a 12-month change in these biomarkers reported previously by Jack and colleagues7. For the calculations presented in the figure, we used the following hypothesized values: MRI = $500; PET = $3,000; plasma markers = $200; Recruitment/consenting/clinical assessment = $1,000. Assessments (excepted with the biomarker of enrichment) were calculated to 2 time-points (baseline and follow-up). We estimated an attrition rate of 10% in the calculations. Δ = longitudinal change. ↓ reduction on the sample size in relation to the whole population.
3.5 Cost-effectiveness analysis of plasma biomarkers for clinical trials
Figure 4B demonstrates that the estimated cost of a clinical trial with biomarkers only using plasma is lower than using neuroimaging biomarkers for surrogacy. Figure 4C shows that, in a trial including all Aβ positive individuals, the total estimated trials cost when considering surrogate biomarkers plus other related are numerically higher using plasma (more than 5-fold at 12 months and 2-fold at 24 months) than neuroimaging biomarkers for surrogacy. Interestingly, when we estimated the total cost of a trial including only individuals with intermediate Aβ levels, the cost was similar using plasma and neuroimaging biomarkers for surrogacy. Cost for clinical trials using other enrichment strategies are describe in Supplemental Figure 4.
3.6 Sample size estimation as a function of multiple drug effects
While the results mentioned above are to test a hypothesized 25% drug effect on the reduction of biomarkers increasing over time, Figure 5 shows a progressive reduction in sample size estimates as a function of potential drug therapies with progressively higher effects on mitigating biomarkers’ changes.
The dots in the curves represent the sample size per study arm as a function of multiple hypothesized drug effects (greater than the tested 25%). For plasma p-tau181, a drug effect large than 60% would represent the need for a sample size of less than 500 CU Aβ positive and that have Centiloid values between 20-40 per study arm. For plasma NfL, a drug effect large than 45% would represent the need for a sample size of less than 500 CU Aβ positive and that have Centiloid values between 20-40 per study arm.
4. Discussion
In this study, we showed that longitudinal changes in plasma p-tau181 were associated with progression to MCI, while changes in NfL were more closely related to aging. Changes in plasma p-tau181 and NfL at 24 months, rather than 12 months, showed the potential to be used as surrogate markers in large-scale preventive clinical trials using CU older individuals. Cost-effectiveness analysis suggested that studies on CU Aβ positive will have higher total cost using plasma p-tau181 and NfL for surrogacy compared to using tau-PET and structural MRI. Interestingly, we also demonstrated that plasma studies using intermediate Aβ levels for population enrichment would be more cost-effective than using the concept of Aβ positivity.
Longitudinal changes in plasma p-tau181 were associated with clinical progression to MCI but not with age. Our results align with previous studies indicating that plasma p-tau181 predicts cognitive decline21, 32-34 and corroborate the notion that plasma p-tau181 can be interpreted as a relatively AD-specific biomarker even in CU individuals21. Given that plasma p-tau181 reflects AD-related Aβ and tau pathologies in the brain35, and that a large proportion of amnestic MCIs are likely to be on the AD pathway36. Thus, our results linking changes in p-tau181 with progression to amnestic MCI further corroborates that this marker can be used to monitor AD-related progression in CU individuals. Interestingly, we observed a negative association between baseline p-tau181 and longitudinal changes in p-tau181, suggesting that plasma p-tau181 progression decelerates in CU individuals that already present high plasma p-tau181 levels. This indicates that changes in p-tau181 are unlikely to be useful for clinical trials focused on late-stage dementia patients, where the plateau of biomarker progression has likely been reached, as was already demonstrated17. Together, these findings indicate that plasma p-tau181 can potentially be used for surrogacy of AD-related clinical progression in clinical trials including CU individuals.
Changes in plasma NfL were not related to progression to amnestic MCI but were highly dependent on the age of participants. These results corroborate previous studies suggesting that plasma NfL is a marker of axonal degeneration non-specific to AD-related progression, increasing as a consequence of several brain processes, including aging13, 15, 37. In contrast to p-tau181, changes in NfL levels were positively associated with their baseline values, suggesting that NfL is still steeply increasing in CU individuals with high plasma NfL concentrations. These results support previous literature associating plasma NfL with age-related progressive neuronal injury37, 38. Together, our findings suggest that plasma NfL could potentially be used as a surrogate marker of age-related neurodegeneration in clinical trials focusing on CU older individuals.
Our analysis supports that longitudinal progression in plasma p-tau181 and NfL biomarkers could potentially be used in 24-month clinical trials in CU older individuals. On the other hand, changes over 12 months showed a very high inter-subject variability and were not significantly different from zero in the CU population. We demonstrated that population enrichment with CU Aβ positive and with intermediate Aβ levels would have a higher impact in reducing the sample size needed for clinical trials using plasma p-tau181 rather than NfL as a surrogate. These results are not surprising since p-tau181 seems to be a more specific marker for AD, while NfL is highly associated with non-specific brain degeneration13, 15, 39-41. However, the fact that clinical trials testing 25% drug effects on biomarker reduction would require more than 5,000 and 2,800 individuals to test changes in p-tau181 and NfL, respectively, suggests that these biomarkers will be more suitable for monitoring large-scale population interventions than for formal randomized controlled trials. We used the standard 25% drug effect in our main analysis to increase comparability with several previous studies6, 7, 30, 42. However, it is worth mentioning that our analysis also suggested that the aforementioned scenario could be different if we consider medications with larger effect sizes. For example, a ∼50% drug effect on either p-tau181 or NfL reduction would lead to the need for a total of ∼1,000 individuals for a clinical trial using plasma biomarker as a surrogate outcome, which could be feasible for randomized controlled trials.
Surprisingly, our results suggest that using longitudinal changes in plasma p-tau181 and NfL would not reduce the cost of clinical trials using Aβ positive individuals compared to using changes in PET/MRI as a surrogate outcome. Although both tau-PET and plasma p-tau181 are postulated to reflect tau deposition in the brain35, 43, longitudinal changes in tau-PET reported in previous studies show more robust estimates, with less intra-subject variably in CU individuals, which translated into a considerably smaller required sample size7. It is known that plasma NfL and MRI are postulated to reflect non-specific neuronal damage43. However, the fact that structural MRI is a relatively inexpensive exam and has relatively robust longitudinal estimates corroborates that it is more cost-effective to use changes in MRI than NfL as a surrogate for neurodegeneration trials in CU individuals. While it is indisputable that blood-based biomarkers are much more accessible and less expensive than neuroimaging for a single patient, our results demonstrate that plasma p-tau181 and NfL are less cost-effective for 12- and 24-month preventive clinical trials testing a 25% drug effect in CU Aβ positive individuals due to the high variability in their longitudinal estimates and the need of larger samples sizes.
Interestingly, this study demonstrated that enrolling individuals with intermediate Aβ levels leads to smaller sample size and total cost for clinical trials using either plasma p-tau181 or NfL as a surrogate compared to studies using the concept of Aβ positivity. This was due to the fact that individuals with higher Aβ levels (centiloid > 40) showed high variability and low average of change in longitudinal plasma estimates. While some (centiloid > 40) showed elevate longitudinal changes, others plateaued their longitudinal progression. Additionally, it was already suggested that is unlikely to detect tau deposition in individuals with centiloid < 40, whereas centiloid > 40 is robustly associated with increased cortical tau deposition 44. Thus, the exclusion of these individuals reduces the standard deviation of changes in plasma biomarkers and consequently increases its effect size, which leads to the need for smaller sample sizes and a lower cost for clinical trials.
The strengths of this study include using data collected in multiple centers, which is more generalizable to multi-site clinical trials than using markers collected in a single site. In addition, our study included a relatively large number of participants. However, our findings must be interpreted while considering limitations. ADNI includes a selective population of highly educated, mostly white participants, generalizable to current clinical trials that have a similar population profile but do not represent a diverse general population. Thus, it would be highly desirable to reproduce our findings in a more diverse population-based cohort45, 46. Furthermore, the use of different blood assays for measuring the plasma biomarkers could lead to different results. Although the 25% drug effect is the standard for this type of study6, 7, 30, the use of different drug effects could change our conclusions. Finally, using a longer follow-up duration could lead to shifts in our results in favor of blood biomarkers, as longitudinal changes in blood markers are likely to become more meaningful over longer time frames.
5. Conclusion
Our results suggest that, in CU older individuals, 24-month changes in plasma p-tau181/ NfL show large inter-subject variability but could potentially be used to monitor large-scale population interventions in CU Aβ positive individuals. Clinical trials using plasma p-tau181 and NfL as surrogates with a population enriched with intermediate levels of Aβ are more cost-effective than trials using Aβ-positive individuals.
Data Availability
All data produced in the present work are contained in the manuscript.
Funding
TAP is supported by the NIH (#R01AG075336 and #R01AG073267) and the Alzheimer’s Association (#AACSF-20-648075). PCL is supported by Alzheimer’s Association (AARFD-22-923814). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712 and #101053962), Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2019-0228), the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003).
Competing interests
HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Pinteon Therapeutics, Red Abbey Labs, reMYND, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). E.R.Z. serves in the scientific advisory board of Next Innovative Therapeutics.
Acknowledgements
Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI; National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica; Biogen; Bristol–Myers Squibb Company; CereSpir; Eisai Inc.; Elan Pharmaceuticals; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche and its affiliated company Genentech; Fujirebio; GE Healthcare; IXICO; Janssen Alzheimer Immunotherapy Research & Development; Johnson & Johnson Pharmaceutical Research & Development; Lumosity; Lundbeck; Merck; Meso Scale Diagnostics; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
6. References
